Do, Khanh T.
Dana-Farber Cancer Institute
4 papers on CoChatORCID 0000-0002-9411-8899
Most cited papers
- Verified
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids
Hill, S. J., Decker, B., Roberts, E. A., Horowitz, N. S., Muto, M. G., Worley, M. J., Feltmate, C. M., Nucci, M. R., Swisher, E. M., Nguyen, H., et al. (2018) · Cancer Discovery
PARP inhibition in cancer therapyOvarian cancer diagnosis and treatment
Cited by 452
- Verified
Institutional implementation of clinical tumor profiling on an unselected cancer population
Sholl, L. M., Do, K., Shivdasani, P., Cerami, E., Dubuc, A. M., Kuo, F. C., Garcia, E. P., Jia, Y., Davineni, P., Abo, R. P., et al. (2016) · JCI Insight
Cancer Genomics and DiagnosticsGenomics and Rare Diseases
Cited by 450
- Verified
Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis)
Kummar, S., O'Sullivan Coyne, G., Do, K. T., Turkbey, B., Meltzer, P. S., Polley, E., Choyke, P. L., Meehan, R., Vilimas, R., Horneffer, Y., et al. (2017) · Journal of Clinical Oncology
Soft tissue tumor case studiesNeurofibromatosis and Schwannoma Cases
Cited by 183
- Verified
Abstract CT032: A phase 1/2, open-label, multicenter, dose escalation and efficacy study of mRNA-2416, a lipid nanoparticle encapsulated mRNA encoding human OX40L, for intratumoral injection alone or in combination with durvalumab for patients with advanced malignancies
Jimeno, A., Gupta, S., Sullivan, R., Do, K. T., Akerley, W. L., Wang, D., Teoh, D., Schalper, K., Zacharek, S. J., Sun, J., et al. (2020) · Cancer Research
Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses
Cited by 41
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free